Champignon Brands Inc. (CSE: SHRM)

The QualityStocks Daily Newsletter would like to spotlight Champignon Brands Inc. (CSE: SHRM).

Champignon Brands Inc. (CSE: SHRM) was featured today in a publication from CBDWire, examining how this year’s Natural Products Expo West Show will be graced by a never seen before product. Dubbed Caliper CBD, it is a dissolvable CBD powder that comes in precise and consistently measured single-serve packets. It is better absorbed than oil-based CBD products, taking effect just minutes after consumption.

Champignon Brands Inc. (CSE: SHRM) is a research-driven company specializing in the formulation and distribution of a suite of artisanal mushroom health supplements. Dedicated to revolutionizing conventional organic teas, coffees and other consumables with the infusion of a proprietary blend of artisanal mushrooms, Champignon’s expanding portfolio is crafted with the health-conscious consumer in mind.

Headquartered in Vancouver, British Columbia, Champignon’s team aims to promote the health and wellness benefits of functional mushrooms, which are used in a wide variety of health care and pharmaceutical products.

Brands

Champignon’s mushroom-derived consumer packaged goods (CPGs) portfolio includes its flagship brand, Vitality Superteas. Each carefully curated Vitality Supertea formulation was developed with the intent of helping individuals enhance and enrich their wellbeing one cup of mushroom-infused tea at a time.

Also in the portfolio are Nourish Force Supertea, a blend of Reishi Ryobus Tea Mix; Mighty Recharge Supertea, created with Lions Mane Tropical Green Ginseng Tea Mix; and Brain Enhance Supertea, a blend of Cordycep Hibiscus and Berries Tea Mix – all of which are formulated with organic ingredients and chosen for their ability to provide unique health and performance benefits.

Champignon’s flagship e-commerce store, VitalitySuperTeas.com, takes advantage of the burgeoning craft mushroom vertical space with a selection of mushroom-infused teas and accessories.

Functional Mushroom Market

Demand for consumer products infused with the nutritional and bioactive benefits of mushrooms is fueling a global market projected to reach $34.3 billion by 2024, growing at a compound annual growth rate of 8.04% from 2019-2024 (ResearchandMarkets), with Europe seen as the fastest growth leader.

According to the market study, in highest demand are products infused with Reishi – a traditional Chinese medicine also known as the “Elixer of Life” and “Mushroom of Immortality – Lions Mane and Cordyceps, followed by other types of medicinal mushrooms.

Advances in Legalization

Legalization of psychedelics for use in medicine is gaining momentum across the United States. Denver, Colorado, and Oakland and Santa Cruz, California, have decriminalized the use of psilocybin, the psychedelic molecule found in various mushrooms, while movements for legalization are gaining ground in Oregon and Iowa, among others. Decriminalize California recently teamed up with the Beckley Foundation to replicate Oakland’s success of decriminalization throughout the state of California.

An increasing number of researchers are turning their attention toward the study of psilocybin as a means to treat otherwise untreatable illnesses. The molecule’s ability to provide landmark treatment options for depression, post-traumatic stress disorder (PTSD), migraines and addiction is gaining widespread acceptance among medical professionals, unicorn investors and accredited institutions.

Potential Applications

Historical data and new scientific studies suggest therapeutic benefits of psychedelics in many areas, including drug addiction, alcoholism, depression, migraines, smoking cessation and post-traumatic stress disorder (PTSD).

The market potential in these areas are significant. To reference just one of the above conditions, the mental health arena has been frequently neglected over the last 30 years, though new research is beginning to further reinforce that psychedelic compounds have the potential to produce more effective treatments than what is currently available.

According to the World Health Organization, 25% of the world’s populous will be afflicted by mental health and/or neurological disorders. Presently, approximately 450 million people currently suffer from such conditions, placing mental disorders among the leading causes of ill-health, productive loss and disability worldwide.

Additionally, PTSD affects approximately 2.2% of the U.S. population; 7.7 million people will have PTSD at some point in their lives. Recent published studies have demonstrated the safety and efficacy of certain psychedelics when administered in a medically supervised and monitored approach.
A renaissance in alternative medicines is emerging, and Champignon has set in motion its strategy to become a key player.

2020 Stealth IP Strategy

Champignon plans to biosynthesize psilocybin within the first three months of conducting laboratory experiments, with the objective of achieving optimized and scaled production of pharmaceutical-grade psilocybin for deployment in clinical settings. This strategy includes:

• Alternative medicine (psilocybin) IP aggregation
• Development of cGMP formulations of bioactive compounds extracted from plants and Fungi
• Drafting of benchmark SOPs (Standard Operating Procedures)
• Patient aggregation, focusing on veterans

Defining a New Asset Class: Psychedelic-Inspired Medicines

In the third quarter of 2020, Champignon – through clinical trials, a compelling IP portfolio and clinical pipeline and drug development platform – plans to advance its pursuit of treatments underpinned by psychedelic substances. This strategy is broken down into two ties:

• Non-Hallucinogenic Medicines
  • Microdosing Psilocybin/LSD
  • MDMA, commonly known as ecstasy

• Hallucinogenic Medicines
  • Psilocybin high dose
  • LSD high dose

Partnerships

Companies worldwide are beginning to incorporate functional mushrooms into their product offerings, taking advantage of growing consumer awareness of known health benefits of the ingredients found in mushrooms.

Champignon in November 2019 entered into a distribution partnership with Eurolife Brands Inc. (CSE: EURO), a leading global markets cannabis brand empowering the medical, recreational and CPG cannabis industry worldwide through a data-driven CBD marketplace supported by exclusive and unbiased physician-backed cannabis education and detailed consumer analytics. Under the agreement, Champignon’s branded products are integrated into Eurolife’s e-commerce platform, along with potential distribution opportunities in select brick-and-mortar retail locations in Europe.

Champignon also has an R&D/production formulation agreement with Drip Coffee Social Ltd., located in Nanaimo, British Columbia, which calls for the infusion of Champignon’s proprietary mushroom extract blend into a suite of cold brew coffee products and signature in-house formulations.

Leadership

Gareth Birdsall, CEO, Corporate Secretary and Director
Gareth Birdsall has more than seven years of experience working in diverse agricultural roles such as the cultivation of various fungi, in particular Cordycepes, Reishi, Lions Mane and Chaga. He is an attendee of the British Columbia Institute of Technology, studying marketing management and finance.

Steven Brohman, CPA, CFO
Steven Brohman has more than 10 years of experience working in a variety of roles with public and private companies. He has had extensive training in the audit of publicly traded companies on the TXS, TSX Venture Exchange and OTC markets, and serves as CFO and director of various public and private companies. Brohman has a bachelor’s degree of business administration and obtained his Chartered Professional Accountant designation.

Jerry Habuda, Director
Jerry Habuda brings to Champignon over 35 years of expertise in law enforcement and specialized units. From 1977 to 2012, he served as a police officer with the Toronto Police Department. During his tenure, he was assigned to the Major Crimes Unit, investigating robberies and home invasions. He was assigned to patrol the Toronto Community Housing projects at Jane/Finch to control drug trafficking and gun violence. Habuda was with the Warrant Unit where he tracked down and arrested wanted criminals. From 1993-1997, he was assigned to the Northwest Drug Squad on undercover and surveillance work, executing narcotic search warrants. Between 2002 and 2004, Habuda headed the Street Violence Task Force, a special unit designed to curb gun and drug violence that was terrorizing the city at the time.

Champignon Brands Inc. (CSE: SHRM), closed Tuesday's trading session at $0.235, up 6.82%, on 2,086,472 volume with 353 trades. The stock's 52-week low/high is $0.225/$0.27.

Recent News

• Dissolvable CBD Powder Unveiled at Natural Products Expo
• EuroLife to Feature Champignon Vitality Teas in Spielhaus Boardgame Cafe
• Champignon Brands Inc. Completes Initial Public Offering

Exro Technologies Inc. (CSE: XRO) (OTCQB: EXROF)

The QualityStocks Daily Newsletter would like to spotlight Exro Technologies Inc. (OTCQB: EXROF).

Exro Technologies (CSE: XRO) (OTCQB: EXROF) this morning announced that the company has been invited to present a white paper titled, ‘The Coil Switching Inverter - A Step Change in Powertrain Design’, to the Car Training Institute (“CTI”), the world's leading summit on advances in automotive transmission, hybrid and electric drive technologies. To view the full press release, visit http://nnw.fm/gKS6r

Exro Technologies Inc. (CSE: XRO) (OTCQB: EXROF), a Canadian technology company, is an innovative pioneer in the energy sector. Exro has developed and commercialized an electric power module (EPM) that integrates into existing motor systems to make them smarter. Exro’s patented technology optimizes existing motor performance by automatically sensing and adapting operating parameters to an optimized state, creating measurable efficiency gains, reduced mechanical components and increased system availability.

Applications

Exro’s technology and efficiency optimization algorithms improve the performance and efficiency of electric motors by manipulating power delivery to individual coils, thereby enabling the ability to expand operating parameters. This novel approach is scalable and can be utilized in most variable torque applications.

The widespread applications of Exro’s technology apply to optimizing the performance of electric vehicles, locomotive traction applications, industrial motors, and other variable torque applications that benefit from smart energy conversion.

Intellectual Property

Exro’s proprietary, patented software controls electric motor coils through individual coil switching. This introduction of intelligence into energy conversion at the level of individual coils results in expanded speed/torque capability, improved machine efficiency, reliability, safety and maintenance across a wider operating range. Exro’s advanced control algorithms create smart, real-time optimized power management.

Exro currently holds 15 patents, with 8 patents pending and additional patents under development. The company continues to expand its IP portfolio to support its goal of becoming a globally recognized leader in leveraging advanced control algorithms to improve the performance, efficiency and longevity of electric motors and generators.

Market Opportunity

Electric motors are the single biggest consumer of electricity. They account for about two-thirds of industrial power consumption and about 45% of global power consumption, according to an analysis by the International Energy Agency. Exro’s technology seeks to give industries a new way to look at energy—from electric vehicles, to industrial equipment, to renewable applications like wind farms; we are improving the way energy is consumed.

Laboratory Expansion

The 6,500-square-foot Exro Innovation Center (EIC), scheduled to open spring of 2020 in Calgary, will transition the current Victoria lab into one Calgary based center. The company’s new laboratory space will expand its service capabilities to customers, provide larger test capabilities, and showcase how Exro’s technology can be applied to dramatically improve the performance of electrical motors.

The EIC will also host collaborative events to explore advances in energy consumption and electric motor innovations, with participants from across Canada and around the world.

Strategic Partnerships

• A strategic agreement with Finland’s Aurora Powertrains Oy, which in 2019 released an all-electric production snowmobile called the “eSled,” will see Exro’s technology added to the Aurora electric powertrain. The snowmobile sector’s economic footprint is estimated at $26 billion in the U.S., $8 billion in Canada, and $5 billion in Europe and Asia.
• An agreement with Potencia in Mexico serving the last mile vehicle segment will integrate Exro’s custom drive and EPM module into small passenger commercial vehicles (taxis) and fleet delivery trucks
• A licensing agreement with Motorino Electric, a leader in the Canadian electric transportation industry, will integrate Exro’s Electric Power Module technology into Motorino’s CTi electric bicycle.

Management

Chief Executive Officer Sue Ozdemir is a proven leader in the innovation and manufacturing of electric motors. She has nine years of accomplishments at General Electric, acting as CCO and the CEO of GE’s Small Industrial Motors Division, overseeing the division’s North American and international markets – ultimately building the division into a $160 million enterprise.

Chief Commercial Officer Josh Sobil is leading the seamless adoption of Exro’s growing product portfolio focused on the mobility segment and opening doors in all segments including agriculture, heavy industry, energy, construction, among others.

Executive Chairman Mark Godsy is a serial technology entrepreneur who has been involved in many top tier ventures, including two of Canada’s most successful biotech companies.

Exro Technologies Inc. (CSE: XRO) (OTCQB: EXROF), closed Tuesday's trading session at $0.2937, up 4.8554%, on 228,294 volume with 46 trades. The average volume for the last 3 months is 117,152 and the stock's 52-week low/high is $0.124389998/$0.522899985.

Recent News

• Exro Technologies Inc. (CSE: XRO) (OTCQB: EXROF) to Present White Paper on Groundbreaking Technology at Car Training Institute Symposium
• Exro Technologies Inc. (CSE: XRO) (OTCQB: EXROF) is “One to Watch”
• Exro Technologies Inc. (CSE: XRO) (OTCQB: EXROF) Announces Closing of Final Tranche of $4.3 Million Private Placement

Bolt Metals Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE)

The QualityStocks Daily Newsletter would like to spotlight Bolt Metals Corp. (OTCQB: PCRCF).

NetworkNewsWire Editorial Coverage: The dramatic rise of electric vehicles (EV) is creating a surge in business for companies mining battery minerals, especially for companies operating in Indonesia, one of the world’s top producers of battery minerals. Bolt Metals Corporation (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE) (BOLT Profile), one of the companies working in Indonesia, recently announced a name change as it rebrands itself a leading resource developer in this growing market.

Bolt Metals Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE) is a Canada-based exploration company focused on the acquisition and development of production-grade battery metals deposits within the Asia-Pacific region, employing a vertically integrated “minerals-to-market” strategy to leverage these assets to their fullest.

Bolt Metals Corp. is advancing its flagship, 100% controlled Cyclops Nickel-Cobalt located in Papua Province, Indonesia with a mandate to become a key contributor to Asia-Pacific’s rapidly expanding electric vehicle and battery supply chain.

The Cyclops project, uniquely positioned within the world’s largest producer of nickel and in proximity to China, the world’s largest “Gigafactory”, features near surface, strong nickel-cobalt mineralization. The property is situated in an area with excellent infrastructure including a nearby workforce, supplies, sealed roads, ocean access, nearby port facility and gentle topography. The project area, nestled on the north coast of Papua, Indonesia, establishes Bolt Metals well within the economically attractive ocean-going transportation range to Asia and its lucrative, growing industrial markets.

Global demand for renewable power is fueling a massive shift from traditional energy supply chain economics to nickel-reliant lithium-ion batteries, the world’s most widely used power source for portable applications such as electric vehicles and other high-tech applications.

Indonesia has recently approved environmental impact studies for factories to produce battery-grade nickel chemicals in Morowali. The approval will allow investors, such as China’s stainless steel giant Tsingshan Group, to continue the construction of their high-pressure acid leaching plants in Morowali, Central Sulawesi.

Ranjeet Sundher, chief executive officer of Bolt Metals, said: “Indonesia continues to make significant strategic decisions, and this latest announcement represents an important step in Bolt Metals’s efforts to benefit from Indonesia’s rapid development as a leading market for all stages of the EV supply chain. With offices in Vancouver, Shanghai and Jakarta, Bolt Metals is well positioned to leverage Asia’s global dominance in the battery manufacturing sector.”

Indonesia’s commitment extends to the very top of government, with Joko Widodo – Indonesia’s President – stating in September 2019 that “for nickel, we want raw materials to be processed in Indonesia. We want added values”. This supports previous pronouncements from key officials, including Indonesian Maritime Minister, Luhut Pandjaitan who remarked that Indonesia will “become the main player in lithium batteries” and that it will “control the world market”.

The country, which is the world’s top nickel ore exporter, has stopped export of unprocessed nickel ore to support this plan.

During 2019 the Company carried out an extensive exploration and development program on Cyclops and achieved successful nickel results with its drilling and bench-scale scoping tests for processing of materials.

Drilling identified significant horizons of nickel mineralization and bench-scale scoping tests returned positive results for processing of this nickel rich material.

The recovery percentages form the bench-scale test program are set out below (for further information, please refer to the Company’s press release of October 28, 2019):

Selected elevated nickel drill results are provided below from the Company’s shallow drilling program (for further information, please refer to the Company’s press releases of March 5, April 1, April 23, June 13, June 20 and September 10, 2019):

2020 will see continued and consistent development in Pacific Rim Cobalt’s strategy as the company continues to set ambitious milestones with the goal of becoming a leading international player in the EV battery metal sector and creating significant long-term shareholder value.

This includes preparations to commission and operate the company’s pilot plant in Canada, which will contain an integrated circuit to produce high-purity nickel and cobalt strip solutions to develop battery-grade nickel and cobalt.

The results of the pilot plant will then be used to establish the design criteria for the subsequent demonstration plant in Indonesia, which will produce nickel and cobalt products suitable to meet market specifications. As well as demonstrating Pacific Rim Cobalt’s ability to produce a product within market specifications, this will also be used to establish the design criteria for the company’s commercial-scale plant.

Pacific Rim Cobalt’s world-class management team includes Ranjeet Sundher, who has over 20 years of capital markets experience. Sundher is also president of Canrim Ventures Ltd., a Singaporean advisory firm specializing in early stage project finance and structure. He previously founded Indogold Exploration, a Jakarta-based mining service firm, and has raised over $40 million for companies in which he was a founder/partner.

Chief Financial Officer Steve Vanry has 25 years of professional experience in senior management positions with public and private natural resources companies, providing expertise in capital markets corporate finance, mergers and acquisitions, regulatory compliance, accounting and financial reporting.

Andre Talaska serves as country manager and technical supervisor. He has over 30 years of experience in the mining and exploration industry and has held senior positions with several companies in Australia and southeast Asia. Shakir Juffry, business development/engineering, is a chemical engineer and extractive metallurgist by background training who has over 20 years of experience in the Indonesian mining and minerals exploration field. Toto Suarto Sajali, operation and development manager, is a mining engineer with over 15 years of experience in Indonesian project assessment, development and operations.

Bolt Metals Corp. (OTCQB: PCRCF), closed Tuesday's trading session at $0.185, up 6.0172%, on 70,629 volume with 19 trades. The average volume for the last 3 months is 33,855 and the stock's 52-week low/high is $0.079999998/$0.259299993.

Recent News

• Electric Vehicle Growth Creates East-Asian Battery Mineral Boom
• Pacific Rim Cobalt Corp. Changes Name to Bolt Metals Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE) in Ramp-up for Asian EV Industry
• Bolt Metals Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE) CEO Discusses Vertical Mineral-to-Market Strategy in Exclusive NetworkNewsAudio Interview

MCTC Holdings Inc. (OTC: MCTC)

The QualityStocks Daily Newsletter would like to spotlight MCTC Holdings Inc. (MCTC).

MCTC Holdings Inc. (OTC: MCTC) was featured today in a publication from HempWireNews, examining how the USDA requirement for testing of hemp by DEA-registered labs would be delayed for the 2020 planting season. And the FDA said that it’s pointless to tell people to stop taking over-the-counter CBD. On Thursday, the USDA issued an update acknowledging complaints submitted by the farmers and the different states.

MCTC Holdings Inc. (OTC: MCTC) is an innovator in the field of cannabinoid nanoparticles and infusion technologies with several important cannabinoid patents filed and an active research and development program underway. The company was reorganized during June of 2019 and announced its intent to enter the cannabis sector and change its corporate identity to Cannabis Global Inc. The company is headquartered in Los Angeles, California.

With the hemp and cannabis industries rapidly expanding in terms of market size, acceptance and number of market participants, MCTC plans to concentrate its efforts on the middle portions of the hemp and cannabis value chain. The company is actively pursuing R&D programs and productization of advanced cannabinoid delivery systems, based on solid polymeric nanoparticles and fibers. These technologies hold the promise to revolutionize the science of cannabinoid bio-enhancement for use in foods, beverages, consumer products and in transdermal applications. Because of nanoparticles’ ability to be quickly absorbed into the bloodstream, nanotechnology has been utilized in the food and drug industry for some time and has the potential for tremendous growth in the cannabis industry (http://nnw.fm/v6RQ6).

Cutting-Edge Technology

MCTC is at the cutting-edge of the cannabis industry’s trends with its emphasis on polymeric nanotechnology. This is not to be confused with the more basic oil-in-water nano-emulsions currently marketed to the food and beverage industry. The company’s polymer-based particles offer significant loading of active ingredients and unmatched flexibility and customization, allowing for myriad combinations of cannabinoids with unique performance characteristics. MCTC believes polymeric nanotechnology particles will be a critical technology area for the cannabinoid formulation marketplace.

The company continues to build its R&D program, specifically researching the development of improving methods to make cannabinoids available to living systems. Instrumental in the research program is the development of novel polymeric nanoparticles and nanofibers. These have the potential to elevate the potential of cannabinoid products in the following ways (http://nnw.fm/cK3Bl):

• Significantly improving bioavailability
• Allowing for ultra-high loading rates
• Enhancing customization of cannabinoid combinations
• Improved dosing precision
• Providing more control in release parameters

MCTC leadership understands the importance of developing intellectual property (IP) in the ever-evolving cannabis industry. A recent Forbes article described IP as “critical for creating true differentiation between companies and their product and service offerings” (http://nnw.fm/57Fjh). Recognizing the importance of IP, MCTC has been consistent in its application for patents to protect its innovative nanotechnology applications.

Patents

MCTC has now filed four patents on its cannabinoid delivery technology systems:

• The company first collaborated with Cannabis Nanosciences Inc. on technologies. This became the basis for its first patent filing on an innovative edible dissolvable film for cannabinoid ingestion.
• Its second patent filing for cannabinoid nanoparticles combined TPGS, a water-soluble form of vitamin E.
• Its third patent filing involved a unique 4th dimension, 3D printed cannabinoid delivery system for beverages.
• Its fourth patent, considered its most significant, broadly covers many aspects of nanoparticles and nano fibers comprising one or more cannabinoids disposed at least partially within a water-soluble medium.

Collaborations

MCTC collaborated with Marijuana Company Inc. (OTCQB: MCOA) subsidiary hempSmart Inc., under a hemp extract and CBD product supply agreement wherein hempSmart will utilize its extensive network of marketing partners to market MCTC’s powered drink mixes and other CBD edibles online. These products are designed for the dry beverage and edibles sector and will be supplied by MCTC. They incorporate the company’s patent-pending cannabinoid infusion technologies and will be trademarked as Hemp You Can Feel (TM) and Gummies You Can Feel (TM).

Leadership

MCTC CEO and chairman Arman Tabatabaei boasts 15 years of management and operations experience and is considered an expert at data collection and analysis relative to resource management, risk forecasting, and profit and loss management. He has acted as a consultant with Cannabis Strategic Ventures (OTCQB: NUGS) and played an instrumental role in improving operations at Sugarmade Inc. (OTCQB: SGMD) relative to the company’s hydroponic growth supplies initiatives.

MCTC founder and director Robert Hymers also brings a seasoned perspective, having had significant experiences in the cannabis industry and as a financial executive and consultant. He is the managing partner of Pinnacle Tax Services in Los Angeles and was previously CFO and director of Marijuana Company of America Inc. (OTC: MCOA). He is currently a member of the Strategic Advisory Board at Massroots Inc. and acts as a consultant to both Cannabis Strategic Ventures Inc. and Sugarmade Inc. Hymers’ background in tax accounting, auditing, SEC reporting, mergers and acquisitions, and corporate finance has immense value in his current position at MCTC Holdings.

MCTC Holdings Inc. (MCTC), closed Tuesday's trading session at $0.22, off by 8.7137%, on 2,108 volume with 2 trades. The average volume for the last 3 months is 16,380 and the stock's 52-week low/high is $0.05/$3.00.

Recent News

• USDA Relaxes DEA Testing Facility Requirement for 2020 Hemp Season
• Colorado Farmers and State Officials Seek Ways to Bypass Federal Hemp Regulation
• MCTC Holdings, Inc. (MCTC) to Host Hemp You Can Feel(TM) Alcohol-Free Cocktails Launch Event for LA Pres

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

Plus Products (CSE: PLUS) (OTCQX: PLPRF), a cannabis and hemp-branded products company in California, has built a brand in the largest competitive market, setting itself up for expansion into new markets. To view the full article, visit http://cnw.fm/0W4Pl. Also today, the company was featured in the 420 with CNW by CannabisNewsWire. The National legalization of hemp under the 2018 Farm Bill provides marijuana business with essential lessons to use when preparing for a highly analyzed, commodity-driven industry. The lessons would especially be valuable to small companies that are well managed.

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

• Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
• Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
• Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
• Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
• Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
• Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed Tuesday's trading session at $0.53, off by 9.5563%, on 53,010 volume with 48 trades. The average volume for the last 3 months is 46,979 and the stock's 52-week low/high is $0.409999996/$4.76000022.

Recent News

• Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) Builds on Strong Cannabis Brand Foundation to Expand into New Markets
• 420 with CNW – What Pot Companies Can Learn from Federal Hemp Legalization
• Data Helps European CBD Firms Navigate the Nascent Industry

Sigma Labs Inc. (NASDAQ: SGLB)

The QualityStocks Daily Newsletter would like to spotlight Sigma Labs Inc. (SGLB).

Sigma Labs (NASDAQ: SGLB), a leading developer of quality assurance software for the commercial 3D printing industry, today announced that it has been awarded a contract to implement its PrintRite3D Real-Time Melt Pool Analytics technology at Northwestern University. To view the full press release, visit http://nnw.fm/ZfOb0.

Sigma Labs Inc. (SGLB) is the only provider of in-process quality-assurance software to the commercial 3D printing metal industry that enables operators of machines making 3D metal parts to offset emerging quality problems, sustain part quality, and avoid rejects. Sigma’s software is the singular solution that enables both real-time, in-process detection of quality control manufacturing irregularities for critical metal parts and then provides the operator the actionable information needed to adjust and mitigate the developing anomaly. Sigma Labs’ software represents a paradigm shift in the quality control process for the manufacture of 3D printed metal components. The nascent 3D metal printing industry is on the verge of radically altering the speed and technical complexity of manufactured parts. Further, it makes possible just-in-time availability of critical components – all at reduced cost, time, waste and weight. 3D printing, heralded as the fourth industrial revolution in manufacturing, will only truly surpass traditional techniques when the additive manufacturing industry moves from “post process” quality control to “in process” quality assurance.

For the industry to move from prototype manufacturing of critical components to economically viable commercial production, the 3D metal printing industry must find ways to dramatically increase production speed and quality yields, and to dramatically decrease the excessive cost of quality control. To achieve these prerequisites and move 3D metal printing into the mainstream, parts must be inspected and certified during the manufacturing process rather than after. Parts in the production process that are developing signs of quality control problems must be identified in real-time and alerts must be issued. The problem, along with the solution, must then be communicated to the machine operator to implement repairs.

Revolutionizing Additive Manufacturing

Sigma Labs, with its PrintRite3D® brand, has established a new benchmark in the development and commercialization of real-time computer aided inspection (“CAI”) solutions. Sigma Labs resolves the major roadblocks and costly quality control challenges that impede the 3D manufacture of precision metal parts. The company’s breakthrough computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance during production, uniquely allowing errors to be corrected in real-time.

Sigma Labs was founded in 2010 by a team of Los Alamos National Labs scientists and engineers to develop and commercially license advanced metallurgical products for the military ordinance, dental implants, and then for additive manufacturing (3D printing). After assessing 3D metal printing technology and the costly, inconsistent quality control issues, Sigma Labs concluded that the enormous potential of 3D metal printing could only scale up if in-process quality-assurance tools were developed to observe, manage and control the manufacturing complexities in such a manner that reliability and repeatability of very high precision quality metal parts could be achieved in the process. Sigma Labs’ patented and third-party validated software has achieved these objectives and now delivers the critical elements needed to unleash the promise of 3D metal printing.

Sigma Labs’ products and services are engineered, manufactured and qualified for use in the highly demanding and hyper precise production environments of the aerospace, defense, transportation, oil and gas, biomedical and other precision-dependent industries.

The Challenge

Additive metal manufacturing combines multiple processes and parts into one single 3D printed part. Due to variances in the additive manufacturing process, parts of consistent quality currently can’t be reliably produced in either large or small quantities without substantial postproduction inspection and rejection costs. Parts are inspected after production using CT scans and other means, so the manufacturer doesn’t know until the very end which of the finished parts meet design specifications. This means lost time, lost profits and inability to economically scale up production.

Innovative Approach

Sigma Labs solves this problem with its patented, in-process quality control technology that informs operators and engineers how to improve both the manufacturing process and quality by capturing meaningful data about inconsistencies in real-time. Sigma Labs is also partnering with OEMs, working toward the visionary introduction of revolutionary closed-loop control that will bypass the machine operator and automatically make in process corrections by reducing machine variations.

Sigma Labs’ next generation technology gives manufacturers the ability to make fast, virtual real-time adjustments so that each finished part is uniform and within critical specifications, thereby improving production quality, decreasing end-users’ risks and waste, and increasing profits and speed to market. Sigma Labs’ PrintRite3D® IPQA Software monitors and assesses the quality of each production part in the 3D additive manufacturing process – layer by layer, and in real-time. This has never been available until now.

Sigma Labs maintains a strong intellectual property portfolio consisting of trade secrets, process know-how and 34 patents either granted, pending or awaiting pre-publication around the globe. These patents encompass the fundamental technologies underlying Sigma Labs’ melt pool process control, data analytics, anomaly detection, signature identification, and future “closed-loop control” of 3D metal printing.

Market Opportunity

Providing advanced quality assurance software to the commercial 3D printing industry is currently a $1.4 billion addressable market expected to grow to $3.9 billion by 2023. Integrating Sigma Labs’ groundbreaking software helps arm the industry with a necessary catalyst to help enable and optimize the fourth industrial revolution in manufacturing.

Sigma Labs’ global client base includes 23 installations across 19 different users. Tier-1 OEM enterprises and end-users such as Siemens, Honeywell, Pratt & Whitney and others are currently evaluating PrintRite3D® for production lines.

Management Team

John Rice, CEO and chairman of the board of directors, has extensive experience as a CEO, lead negotiator, turnaround expert, business financier and crisis management executive/consultant. Prior to becoming chair and CEO of Sigma Labs, he was the CEO of a successful turn-around of a Coca-Cola Bottling Company. Rice has led a variety of companies in diverse business sectors and worked on a host of products and technologies including design and manufacture of high-end jet engine test equipment for the U.S. Airforce, chaff dispensers for F16s, software for modeling naval exercises, software for controlling warehouse distribution systems, medical radioisotopes, cancer detection, and cybersecurity. He is an honor’s graduate of Harvard College.

Darren Beckett, CTO, has over 20 years of experience in the semiconductor industry, including Intel Corporation, where he held various technical and managerial positions. His expertise in process engineering for advanced manufacturing technology includes statistical process control for fabrication of semiconductor devices.

CFO Frank D. Orzechowski also serves as treasurer, principal accounting officer, principal financial officer and corporate secretary. He has more than 30 years of distinguished financial and operational experience. Orzechowski began his career at Coopers & Lybrand in 1982, received his CPA certification in 1984, and received his Bachelor of Science in Business Administration with a major in accounting from Georgetown University in 1982.

Ronald Fisher, vice president of business development, is leading the commercialization of PrintRite3D® 5.0. Fisher is a mechanical engineer with hands-on experience in quality, manufacturing and product development. He has distinguished himself as a lead sales and marketing officer as well as a chief operating officer most recently before joining Sigma in technology startup that grew from market entry to successful exit by merger-acquisition.

Sigma Labs Inc. (SGLB), closed Tuesday's trading session at $5.61, off by 0.883392%, on 68,889 volume with 425 trades. The average volume for the last 3 months is 86,345 and the stock's 52-week low/high is $4.40000009/$20.216999.

Recent News

• Sigma Labs, Inc. (NASDAQ: SGLB) Awarded Contract to Implement PrintRite3D Real-Time Melt Pool Analytics Technology at Northwestern University
• Will Sigma Labs Inc. (NASDAQ: SGLB) Be Big Winner from Global Supply Chain Transformation by Becoming Standard for 3D-Printing QC Solutions?
• Sigma Labs Inc. (NASDAQ: SGLB) Positioned to Leverage Opportunities in Aviation Industry with In-Process QC Software for 3D Metal Parts

SRAX Inc. (NASDAQ: SRAX)

The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

SRAX Inc.’s (NASDAQ: SRAX) BIGtoken platform successfully propelled a 2019 holiday season omnichannel campaign at Walmart for leading packaged goods company Kraft Heinz – achieving impressive results and exceeding the client’s goals. SRAX COO Kristoffer Nelson said BIGtoken utilized opt-in panels and offers plus scanned receipts to identify incremental groups of buyers to increase both sales and return on ad spend for Kraft Heinz.

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

• SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
• SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
• SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
• SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
• SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
• SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.

BIGtoken

BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.

Leadership

Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Tuesday's trading session at $2.54, off by 6.2731%, on 105,629 volume with 446 trades. The average volume for the last 3 months is 97,711 and the stock's 52-week low/high is $1.04999995/$5.8499999.

Recent News

• SRAX Inc. (NASDAQ: SRAX) BIGtoken Platform Powers Kraft Heinz Holiday Campaign That Delivers Impressive Sales Lift
• SRAX Inc. (NASDAQ: SRAX) Announces Major CPG Company’s Results to Generate 6 to 1 ROAS and 4.5% Incremental Sales Lift Through Employment of BIGtoken
• SRAX Inc. (NASDAQ: SRAX) Uncovers Millennials’ Love for Experience-Based Gifts

Nightfood Holdings, Inc. (OTCQB: NGTF)

The QualityStocks Daily Newsletter would like to spotlight Nightfood Holdings, Inc. (NGTF).

Nightfood Holdings (OTCQB: NGTF), the better-for-you ice cream recently recommended as the Official Ice Cream of the American Pregnancy Association (“APA”), today announced that it will present to thousands of OBGYNs at the upcoming annual conference of the American College of Obstetricians and Gynecologists (“ACOG”). This year’s conference is slated to be held in Seattle on April 24 - 27, 2020, and attract over 5,000 attendees, including several thousand physicians. To view the full press release, visit http://nnw.fm/A9IcB. Also today, NetworkNewsWire released a report on the company detailing how Nightfood Holdings’ founder and CEO Sean Folkson recently joined Stuart Smith on SmallCapVoice.com (http://nnw.fm/9L1Yv) to discuss the announcement that NGTF’s better-for-you ice cream is now the recommended ice cream for pregnant women all across the United States, a market of over three million women. This official endorsement comes from the American Pregnancy Association (APA), and it carries significant weight for Nightfood’s market penetration. In the interview, Folkson discussed the media buzz created by the new endorsement from the APA (http://nnw.fm/5uNvD).

Nightfood Holdings, Inc. (OTCQB: NGTF), a pioneering consumer goods brand development company headquartered in Tarrytown, New York, owns Nightfood, Inc., creator of delicious, award-winning and better-for-you ice cream formulated by sleep and nutrition experts, and its wholly owned subsidiary MJ Munchies, Inc., which seeks to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. Known as “The Nighttime Snack Company,” Nightfood Inc. is focused on improving late-night snacking for consumers and solving America’s $50 billion-dollar nighttime snacking problem.

Nightfood Ice Cream

Nightfood’s higher-protein and sleep-friendly ice cream won the 2019 Product of the Year Award in the ice cream category in a Kantar survey of over 40,000 consumers. The annual Product of the Year survey, the world’s largest consumer-voted award for product innovation, is conducted by Kantar, a global leader in consumer research. In beating out the other finalists, consumers indicated that Nightfood’s one-of-a-kind innovation and unique value proposition made it a clear-cut winner in the ice cream space and a brand they were highly motivated to try.

Nightfood has secured distribution in several major regional supermarket chains and has landed media coverage in major outlets such as The Today Show, The Wall Street Journal, Oprah Magazine, USA Today, The Washington Post, Parents Magazine, and many more.

Over 80% of consumers snack regularly at night, and the most popular choices are cookies, chips, candy, and, of course, ice cream. These are understood to be both unhealthy and sleep-disruptive.

Research indicates that human biological programming combined with the trappings of modern life combine to drive this unhealthy behavior pattern. Every week, hundreds of millions of Americans combine to spend an estimated $1B on snacks consumed between dinner and bed.

In a recent Harris Poll online study, 54% of consumers who snack at night reported often feeling guilty about their nighttime snack choices. 58% said they wish they felt more in control of their nighttime snacking.

Nightfood management believes that the company that solves this massive consumer problem can become a national brand with a billion-dollar valuation.

Formulated by leading sleep and nutrition experts, including America’s most prominent sleep expert, Dr. Michael Breus, Nightfood’s higher protein/higher fiber, and lower sugar ice cream delivers great ice cream taste and texture, while minimizing sleep-disruptive ingredients such as caffeine, excess sugar, and excess fat and calories. The addition of certain minerals, enzymes and amino acids, which research suggests can support sleep quality, is another bonus. Nightfood only uses hormone-free milk, is certified Kosher, and offers eight original flavors, five of which are gluten-free. Nightfood ice cream also uses all-natural sweeteners with no Erythritol, no sucralose, or other artificial sweeteners.

Nightfood has developed a dynamic infographic resource that clearly illustrates the size and scope of the largely untapped nighttime snack category (http://NightSnacking.com). Americans everywhere are likely to identify with the infographic’s results that vividly illustrate late night snacking by age group, popular snack choice, and amount of money spent each week on feeding after-hour snack attacks. Available in eight delicious flavors, Nightfood ice cream can help consumers satisfy nighttime cravings in a better, healthier, more sleep-friendly way.

MJ Munchies, Inc.

MJ Munchies, Inc. was formed in 2018 as a new, wholly owned subsidiary of Nightfood Holdings, Inc. to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. The Company is seeking licensing opportunities to market such products under the brand name “Half-Baked,” for which they’ve successfully secured trademark rights.

Management Team

Nightfood founder and CEO Sean Folkson is a formerly frustrated nighttime snacker whose late-night cravings led him to seek a better solution for himself and others through the creation, marketing and distribution of the Nightfood product line. Folkson also founded internet marketing company AffiliatePros.com which provided the startup capital to launch Specialty Equipment Direct, an online distributor of floor removal equipment that quickly grew to 7-figure revenues. Folkson received a bachelor’s degree in business administration with a concentration in marketing from S.U.N.Y Albany, New York, in 1991.

Jim Christensen, vice president of Nightfood Ice Cream, is the former vice president of Ice Cream Sales with global ice cream giant Unilever. In his over 20 years at Unilever, Christensen led sales and distribution initiatives for brands such as Ben & Jerry’s, Klondike, Breyers and Good Humor. Christensen joined the Nightfood team in June of 2018 with the directive to launch Nightfood ice cream rapidly into national distribution. Understanding that the overwhelming majority of at-home ice cream consumption occurs in the hours before bed, Christensen has identified Nightfood as the next evolution in better-for-you ice cream.

CFO Mark Noffke, CPA, has over 37 years of experience as a seasoned financial and management professional. He has served as chief financial officer of several small-cap public companies since 2004 where he oversaw virtually every aspect of the company’s operations, administration, customer service and human resources. Noffke has a bachelor’s degree in accounting from Valparaiso University in Indiana.

Advisory Board

The Nightfood advisory board includes Tom Morse, founder of 5-Hour Energy and Living Essentials, LLC.; Doron Stern, former vice president of marketing at Chobani and Popcorn, Indiana; restaurateur and celebrity Chef Chris Santos; Paul Jarrett, CEO of fast-growing nutrition startup BuluBox; Eric Egeland, president of Capacity Consulting Inc.; Dr. Michael A. Grandner, director/Sleep and Health Research Program at the University of Arizona; Dr. Michael Breus, sleep expert and best-selling author known to millions as The Sleep Doctor(TM); Dr. Lauren Broch, resident nutrition, sleep disorder expert and a member of the scientific advisory board.

Nightfood Holdings, Inc. (NGTF), closed Tuesday's trading session at $0.30, off by 4.7619%, on 145,149 volume with 56 trades. The average volume for the last 3 months is 161,070 and the stock's 52-week low/high is $0.187999993/$0.920000016.

Recent News

• Nightfood Holdings Inc. (NGTF), the Official Ice Cream of the APA, to Exhibit at the American College of Obstetricians and Gynecologists 2020 Conference
• Nightfood Holdings Inc. (NGTF) CEO Calls Recommendation as Official Ice Cream for Pregnant Women a ‘Game Changer’
• Nightfood Holdings Inc.’s (NGTF) Ice Cream to Hit the Shelves Across Iconic Chicagoland Jewel-Osco Supermarket Chain

Cannabis Strategic Ventures, Inc. (OTCQB: NUGS)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Strategic Ventures, Inc. (OTCQB: NUGS).

Cannabis Strategic Ventures (OTCQB: NUGS), an emerging leader in the U.S. and California cannabis marketplaces, today announced robust growth and significant financial improvements for the most recently completed financial period ending Dec. 31, 2019. To view the full press release, visit http://cnw.fm/w4OV7. Also today, the company was highlighted in the Investor Ideas Potcast, from Investorideas.com, http://ibn.fm/ZA6WM.

Cannabis Strategic Ventures, Inc. (OTCQB: NUGS), headquartered in Los Angeles, California, is focused on supporting entrepreneurial growth within the fast-growing legal cannabis sector. Through a selective portfolio of subsidiaries, Cannabis Strategic Ventures offers outsourced personnel solutions tailor-made to match the growth dynamics of cannabis cultivators, manufacturers, dispensaries and other cannabis marketplace participants. The company also pursues investment opportunities in the areas of real estate, cultivation, extraction, distribution, packaging, dispensary operations, and branded products within the cannabis space.

The legalization of adult-use sales in California is expected to create nearly 99,000 cannabis industry jobs in the state by 2021, representing about a third of all cannabis jobs nationwide, and 146,000 jobs overall when indirect and induced efforts are considered, according to Arcview Market Research. By 2021, direct cannabis industry employment will top 291,500 FTE jobs, with a total employment effect of nearly 414,000 FTEs across all legal cannabis states, according to the report.

Cannabis Strategic Ventures believes its staffing capabilities will be in a similar state of demand. The company in April 2018 completed a definitive agreement to acquire Worldwide Staffing Group, Inc., which booked approximately $1.5 million in revenues in 2017.

Worldwide will operate within Cannabis Strategic Ventures as an independent and separate wholly owned subsidiary providing strictly non-cannabis related employment and staffing services. As Worldwide continues to expand its operations in general clerical and administrative, marketing, accounting, and other verticals, Cannabis Strategic Ventures will leverage the subsidiary’s expertise to expand its business operations further into the cannabis staffing arena, with an emphasis on the California markets.

Cannabis Strategic Ventures’ BudHire™ subsidiary is an outsourced employment service specifically designed to meet the needs of growing cannabis-related business operations, utilizes a proven recruiting formula to match the most qualified candidates to a broad spectrum of cannabis-related jobs. Under the BudHire™ brand, Cannabis Strategic Ventures offers temporary, seasonal, permanent staffing solutions, as well as professional employment organization services and human resources consulting to the cannabis industry.

Cannabis Strategic Ventures portfolio also includes Pure Applied Sciences Inc. and its brand “PureOrganix™,” a line of high quality concentrate, organic and pure cannabis oils that conform with Current Good Manufacturing Practices (cGMP) and meet FDA guidelines for Active Pharmaceuticals Products (API). The acquisition includes all intellectual properties, including formulations and technologies, and related accessories of Pure Applied Sciences.

Cannabis Strategic Ventures Pure Applied Sciences subsidiary, has a cannabis concentrate extraction services agreement with CP Logistics LLC (“CPL”), a wholly owned U.S. subsidiary of Sunniva Inc. (CSE:SNN) (OTCQX:SNNVF). Under this agreement, CPL will perform white label services producing high quality, ultra-purified cannabis extracts out of its Sun-Oil Facility in Cathedral City, California, for Pure Applied Sciences under the Pure Organix brand name.

The management team at Cannabis Strategic Ventures believes there is incredible opportunity to carve-out and control specific industry niches, to create unique cannabis consumer branded products, and to expand into other sub-sectors of the cannabis marketplace.

Cannabis Strategic Ventures, Inc. (OTCQB: NUGS), closed Tuesday's trading session at $0.078, up 6.8493%, on 936,783 volume with 127 trades. The average volume for the last 3 months is 1,288,463 and the stock's 52-week low/high is $0.025499999/$1.50999999.

Recent News

• Cannabis Strategic Ventures, Inc. (NUGS) Announces 91% Sequential Growth to $1.35 Million and Significant Financial Improvements
• Investor Ideas Potcasts, Cannabis News and Stocks on the Move
• 420 with CNW – Italian Scientists Announce Discovery of Two New Marijuana Cannabinoids

Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX)

The QualityStocks Daily Newsletter would like to spotlight Foresight Autonomous Holdings Ltd. (FRSX).

Foresight Autonomous Holdings (NASDAQ: FRSX) (TASE: FRSX), an innovator in automotive vision systems, this morning announced that the company’s Chief Financial Officer Eli Yoresh and Vice President of Business Development Doron Cohadier will present at the 32nd Annual ROTH Conference, which is taking place from March 15-17, 2020 at The Ritz Carlton, Laguna Niguel, CA. To view the webcast, visit http://nnw.fm/tD4au. To view the full press release, visit http://nnw.fm/7sZ0S.

Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX), founded in 2015 and headquartered in Israel, is a technological innovator in automotive vision systems and driver assistance technology. Through its wholly owned subsidiary, Foresight Automotive Ltd., Foresight is engaged in the design, development and commercialization of stereo/quad-camera vision systems and V2X cellular-based solutions for the automotive industry based on 3D video analysis, advanced algorithms for image processing and sensor fusion. The company’s powerful and patented stereoscopic technology is derived from field-proven technology that has been deployed throughout the world for almost two decades.

Foresight’s innovative autonomous driving solutions are based on mature, proprietary stereoscopic image technology that uses two synchronized cameras to mimic human depth perception and produce a three-dimensional image. This 3D image can anticipate possible collisions with other vehicles, cyclists, pedestrians and other obstacles. The technology provides highly accurate real-time alerts about the vehicle’s surroundings while in motion. The systems are designed to improve driving safety by enabling highly accurate and reliable threat detection while ensuring the lowest rates of false alerts.

The company’s patents provide IP protection for its robust and proven proprietary stereoscopic technology, which was developed using the security technology of Foresight’s major shareholder, Magna B.S.P.

Foresight has developed three main products:

• QuadSight™. This breakthrough detection system sets the bar for autonomous vehicle vision. It features nearly 100 percent obstacle detection with almost zero false alerts and operates optimally under all weather and lighting conditions, including darkness, rain, fog, haze and glare. QuadSight™ is the first quad-camera multi-spectral vision solution of its kind, driven by advanced and proven image processing algorithms. The system consists of two sets of stereoscopic infra-red and visible-light cameras that enable highly accurate and reliable obstacle detection for seamless 24/7 vision.
• Eyes-On™. This solution uses advanced algorithms for accurate depth analysis and obstacle detection to provide a unique stereo vision Advanced Driver Assistance System (ADAS). It can detect all potential obstacles regardless of shape, form or material, including other vehicles, cyclists, pedestrians and animals. It has an accuracy and reliability of almost 100 percent and near zero false alerts.
• Eye-Net™. This is a cellular-based accident prevention solution that is designed to provide real-time pre-collision alerts to vehicles and pedestrians. This proprietary system is deployed on smartphones and cloud-based servers operating on existing cellular networks, and it eliminates the need for additional designated hardware. Eye-Net™ is designed to provide a complementary layer of protection to advanced driver assistance systems and extends this protection to road users who are not in direct line of sight. It is optimally designed for both urban environments and high-speed scenarios to provide protection for the most vulnerable road users. On March 28, 2018, Foresight announced that it had completed a successful feasibility study of its Eye-Net™ accident prevention solution involving 120 users of Android and iOS cell phones located across Israel.

In 2017, Foresight sought more opportunities within the international market. The Company signed pilot agreements with three leading car manufacturers in China and completed pilot projects meeting all pre-defined requirements and criteria. In addition, FRSX completed a pilot project with Uniti Sweden.

Studies by the Insurance Institute for Highway Safety continue to emphasize the dramatic reduction in accidents and injury-related crashes reported when vehicles are equipped with collision avoidance systems. A recent study by the Institute states that the rate of single-vehicle, sideswipe and head-on crashes was 11 percent lower in vehicles with the warning systems. More importantly, the study shows collision avoidance technology cut the rates of injury crashes of the same type by 21 percent.

Foresight Autonomous Holdings, Inc. also holds a 32 percent interest in RailVision, a company that develops advanced systems for railway safety and maintenance. RailVision has successfully completed 13 tests in Israel, Germany, Italy and Switzerland in addition to a real-time system test with a European railway operator. Over the course of 2017, RailVision successfully completed rounds of financing totaling $5.8 million and started the process of licensing the system according to European standards.

Haim Siboni is the founder of Foresight and has served as the company’s chief executive officer and director since 2015. Siboni, a passionate entrepreneur, has an extensive background in the marketing and business management sectors in the fields of electronics, video, TV, multimedia, computerized systems, line and wireless telecommunication, design and development of systems and devices, including electro-optic radar systems. He is the founder and CEO of Magna B.S.P., Foresight’s major shareholder and a leading innovator in the field of homeland security surveillance solutions.

Foresight Autonomous Holdings Ltd. (FRSX), closed Tuesday's trading session at $0.98, up 1.3444%, on 3,899 volume with 28 trades. The average volume for the last 3 months is 39,068 and the stock's 52-week low/high is $0.697000026/$2.94000005.

Recent News

• Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX) Management to Provide Presentation at 32nd Annual ROTH Conference
• Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX) Announces Receipt of QuadSight(R) Prototype Order from Multi-Billion Dollar Japanese Vehicle Manufacturer
• Foresight Autonomous Holdings Ltd.’s (NASDAQ: FRSX) (TASE: FRSX) Eye-Net Mobile Named a Finalist in GSMA’s MWC Barcelona 2020 Global Mobile Awards

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing treatments for cancer and other serious diseases, today announced that it will present at the third annual LD Micro Virtual Conference at 1:40 p.m. EST on Wednesday, March 4. To access the live presentation, visit http://nnw.fm/XiS1t. To view the full press release, visit http://nnw.fm/UEd2Y. Also today, the company was highlighted in a publication from Financialnewsmedia.com, examining how the global Glioblastoma multiforme (GBM) drugs market, is projected to reach nearly $1.4 billion by 2025, expanding at a CAGR of 12.6% during the forecast period, driven by rising geriatric population, growing incidence cases and rich clinical pipeline of new products. Glioblastoma is the most common primary malignant form of brain cancer.

Genprex Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.

Genprex Inc. (NASDAQ: GNPX), closed Tuesday's trading session at $4.43, off by 7.1279%, on 2,793,811 volume with 7,272 trades. The average volume for the last 3 months is 7,438,318 and the stock's 52-week low/high is $0.231000006/$7.0300002.

Recent News

• Genprex, Inc. (NASDAQ: GNPX) to Present at the Third Annual LD Micro Virtual Conference
• Prognosis for Treatment of Glioblastoma Multiforme Expected to Impact Market Growth for Drug Makers
• Genprex Closes $25.5 million Offerings Successfully

The Supreme Cannabis Company Inc. (TSX: FIRE) (OTC: SPRWF)

The QualityStocks Daily Newsletter would like to spotlight Supreme Cannabis Company Inc. (OTC: SPRWF).

Supreme Cannabis Company (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) recently signed a landmark sales agency agreement with one of North America’s leading distributors of cannabis accessories — humble+fume (http://cnw.fm/nt7Jw). To view the full article, visit http://cnw.fm/zuJV8

Supreme Cannabis Company Inc. (TSX: FIRE) (OTC: SPRWF) is committed to providing premium brands and products that reflect the company’s knowledgeable customers, passionate employees and culture of innovation. The company aims to grow the world’s best legal cannabis and become a leader in the global industry. Supreme Cannabis calls its Toronto Venture Exchange stock symbol, “FIRE,” a testament to the company’s passion for cannabis and obsession with quality.

Supreme Cannabis believes the world is ready to follow Canada’s lead by ending the 100-year cannabis prohibition and, as one of Canada’s most premium cannabis producers, the company sees itself at the center of this global shift.

A key piece of Supreme Cannabis’ ability to fulfill its mission is its flagship brand, 7ACRES, a wholly owned subsidiary that operates a 440,000-square-foot hybrid cultivation facility in Kincardine, Ontario. 7ACRES is focused on building a core competency in scaled high-quality cannabis production. With a best-in-class cultivation facility producing a competitive product that fuels a leading premium brand, Supreme Cannabis has achieved a differentiated advantage in cultivation IP, products and branding. The company’s foundational investment in premium cultivation has secured it a leadership position in the industry as the Canadian market becomes more competitive and matures.

Since legalization, 7ACRES has brought five premium flower strains to market in Canada. The demand for 7ACRES product continues with the company’s most recent launch of Jack Haze, a new proprietary premium cultivar. The company’s first sativa-dominant strain, Jack Haze offers rare sensory characteristics, delivering high THC content with a terpinolene forward profile, including a complex aroma with notes of citrus, pine and warm spice. As it develops its next winning strain, 7ACRES continues to prioritize subjective quality. In the Canadian cannabis market, this approach has established 7ACRES as a well-known premium brand that commands premium pricing coast-to-coast.

In addition to 7ACRES, Supreme Cannabis has built a diversified portfolio of focused consumer-driven brands:

• Sugarleaf by 7AC – this new brand widens Supreme Cannabis’ product offerings and targets consumers who are looking for more refined, milder consumption experience as they discover their own cannabis taste preferences and desires. Product formats under this brand are focused on offering consumers elegant and convenient cannabis experiences.
• Blissco — dedicated to providing wellness focused consumers with premium cannabis products, education, and outstanding customer care. Blissco is focused on bringing its collection of premium whole-flower CBD oils to market.
• Truverra — focused on being a global leader in the development, production and marketing of hemp and cannabis-derived medicinal products with clinically proven efficacy. With over 25 SKUs sold online in the UK and Europe, Truverra is ideally positioned to address emerging international cannabis opportunities.
• Khalifa Kush Enterprises — formed through a prestigious international partnership with Khalifa Kush Enterprises (KKE) Canada, the Canadian counterpart to the popular U.S. cannabis brand KKE formed by Wiz Khalifa. Together, Supreme Cannabis and KKE Canada are developing and launching a lineup of premium cannabis products, including a future line based on the well-known Khalifa Kush strain.

Each of Supreme Cannabs’ brands and partnerships have been strategically identified and designed to support the company’s mission to enhance the lives of consumers through positive cannabis experiences. Equally important to delivering desirable consumer experiences is the infrastructure supporting the company’s brands and products. From seed to sale, supreme cannabis continues to build an impressive group of operating assets that serve key functions throughout the value chain:

• Cultivation – for starters, there is Supreme Cannabis’ foundational flagship asset, its 440,000-square-foot cultivation facility in Kincardine, Ontario. With over 600 employees, 24 grow rooms, and best-in-class processing equipment and procedures, this facility is expected to reach an annual production capacity of 50,000 kilograms in the near-term. In this purpose-built facility, the company grows small-batch high-quality cannabis from 10,000-square-foot grow rooms and completes a proprietary hang-dry for up to two weeks.
• Extraction – with the acquisition of Blissco in fiscal 2019, in addition to the Blissco wellness brand, Supreme Cannabis gained a 12,000-square-foot dedicated extraction facility in Langley, BC. This facility conducts both C02 and ethanol extraction and with the recent receipt of its oil sales license from Health Canada, it now produces Blissco branded CBD oils and expects to fill vaporizer pods for a partnership between the company’s 7ACRES brand and Pax Labs.
• Manufacturing – most recently, the company announced its 107,000-square-foot processing, packaging and manufacturing facility in Kitchener, naming the facility Supreme Cannabis Kitchener. In Q4 FY2020, the company expects to begin whole flower packaging and pre-roll manufacturing for Supreme Cannabis brands at the Kitchener Facility. In the long-term, in additional to processing its own inputs, Supreme Cannabis intends generate incremental revenue by packaging, distributing and branding third-party cannabis inputs from quality-focused cultivators.
• R&D and Product Testing – In Q1 FY2020, Supreme Cannabis closed the acquisition of Truverra and acquired a 5,000-square-foot facility licensed under Canadian Clinical Cannabinoids Inc. in Scarborough, Ontario (“Supreme Cannabis Scarborough”). Supreme Cannabis Scarborough provides R&D space for the company to test new products and develop medicinal science intellectual property. In the near-term, with the legalization of 2.0 cannabis products, this centre for innovation will be testing and bringing concentrate products to market under the 7ACRES brand.

Supreme is committed to continue to identify new opportunities to grow and strengthen its impressive portfolio of operating assets and brands and scale its strong Canadian business globally.

Supreme Cannabis Company Inc. (OTC: SPRWF), closed Tuesday's trading session at $0.22, off by 4.6381%, on 330,967 volume with 176 trades. The average volume for the last 3 months is 468,180 and the stock's 52-week low/high is $0.197400003/$1.75.

Recent News

• Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) Inks Sales Agency Agreement with humble+fume
• CBD Focus Should Also Be Directed To Seniors, A Wider Market Is Great News For Companies In The CBD Sector
• The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) Signs Landmark Sales Agreement with Leading Cannabis Distributor

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

Predictive Oncology (POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.

Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:

• A database of clinically validated historical and outcome data from patient tumors
• An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
• A “smart” patient-derived tumor profiling platform
• An in-house bioinformatics artificial intelligence (AI) platform
• A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
• An FDA-approved fluid collection and disposal system

Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from the company’s trove of more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies. This database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory without the use of rats or mice, allowing for the identification of biomarkers indicative of cancer. This methodology “fools” the tumor into thinking it is still in the body. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and helps categorize an individual patient’s heterogeneous tumor samples to enable development of patient-specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY® System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Competitive Advantage

Precision medicine has become the holy grail of cancer therapeutics. Data driven predictive models of tumors and their responses are critical in both new drug development and individualized patient treatment. The race has begun to model various tumors, which takes 5 to 7 years of clinical evaluation to establish historical and outcome data.

Predictive Oncology enjoys significant competitive advantage. The company already has a vast historical collection of tumors and related data, plus the ability to obtain existing associated outcome data. While others wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine to reality. Predictive Oncology already has the clinical data, including how a tumor responded to certain drugs, an in-house bioinformatics AI platform, and only needs to do the tumor sequencing. The significance is underscored by the collaboration with UPMC Magee-Women’s Hospital, designed to reveal which mutations responded to which drug then develop powerful predictive models for future testing and treatment.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Gerald Vardzel, President of Helomics, has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.

Dr. Mark Collins, Chief Information Officer of Helomics, has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.

Predictive Oncology (POAI), closed Tuesday's trading session at $2.35, up 5.8559%, on 70,125 volume with 389 trades. The average volume for the last 3 months is 150,734 and the stock's 52-week low/high is $1.96000003/$8.50.

Recent News

• Predictive Oncology Inc.’s (NASDAQ: POAI) Proposed Acquisition Further Positions it to Aid Efforts to Accelerate Discovery of New Anti-Cancers, Anti-Virals and Vaccines
• Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Employs Unique Cancer-Research Approach
• Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Selects Manufacturer, Distributor of Innovative Cell-Culture Media

Trxade Group Inc. (NASDAQ: MEDS)

The QualityStocks Daily Newsletter would like to spotlight Trxade Group Inc. (NASDAQ: MEDS).

Trxade Group Inc. (NASDAQ: MEDS) is an integrated pharmaceutical services company that offers a unique combination of a web-based purchasing platform (www.trxade.com) for transactions between independent pharmacists and drug distributors (B2B); a network of pharmacies with E-Hub software; a mail order pharmacy; and warehouse and drug delivery services. This synergistic combination of product offerings and superior data analytics is poised to benefit all stakeholders and consumers within the pharmaceutical industry.

Trxade will leverage and scale its fully integrated model to execute the following growth strategies:

• Increase share of pharmacist drug purchasing
• Additional SKUs and expand product breath
• Partner with Specialty and International Mfg.
• Expand mail order licenses to all 50 states
• Scale Delivmeds for consumer delivery nationwide
• Integration with telemedicine
• M&A Opportunities within drug value chain

Founded in 2010 and headquartered in Tampa, Florida, Trxade’s overarching corporate strategy is to penetrate the existing retail independent pharmacy marketplace and diversify the company’s pharmaceutical mix with additional specialty and acute care products. Trxade is advancing on this mission by focusing on three key niches in the health care market.

Business-to-Business (B2B)

The $330 billion U.S. pharmaceutical industry is comprised of more than 65,000 pharmacy facilities and 1,500 state-licensed suppliers. Roughly 24,000 of these facilities are independent pharmacies, which collectively spend approximately $93 billion a year on branded and generic drugs.

Trxade targets these independent pharmacies, leveraging a robust, “E-Bay/Kayak-like” technology platform with optimum buyer/seller pricing algorithms, product availability, and predictive data analytics features.

Trxade currently serves and transacts with more than one-third (10,250) of these independent pharmacies and facilitates over $10 million of drug purchases a month!

Consumer

Trxade also targets the “consumer side” of the pharmaceutical industry, aiming to lower prescription drug costs by attacking the inefficient value chain; offering drug price transparency and efficient buying; and, delivering drugs DIRECT to independent pharmacists and consumers.

The company operates a full-service mail order pharmacy for U.S. consumers, as well as a mobile app called “Delivmeds” (http://www.delivmeds.com) which enables SAME DAY home delivery of dispensed prescriptions.

Retail

Trxade’s Managed Services Organization (“TrxadeMSO”) enables its member independent retail pharmacies to get patients, process orders, and deliver or ship prescriptions to patients. TrxadeMSO provides access to encompassing network of pharmacies through the E-Hub software, allowing for timely and comprehensive medication fulfillment.

These offerings ensure the best-suited pharmacy receives the patient’s information, thereby ensuring appropriate medication coverage based on the patient’s location, payor coverage, and medication access/inventory. This will save the clinicians and their staff time as they benefit from efficiency and enhanced workflow management in script processing and fulfillment.

Health Care Market 

The U.S. health care market currently hovers near $4 trillion and is expected to grow as the general population ages. This growth will have greater impact on consumers as out-of-pocket expenses also rise. Additionally, drug costs are paced to increase faster than the overall health care and well above inflation.

Drug pricing is variable, and reimbursement is squeezing profits. This provides significant opportunity for the Trxade model of price visibility and profit optimization.

Trxade’s fair online market platform targets the nation’s retail community and independent pharmacies, of which there are approximately 24,000 nationwide. TRxADE has found that independent pharmacies, in order to be cost-effective, often operate with minimal staff and conduct up-to-the minute price checks. The TRxADE S2P platform gives these pharmacists the ability to easily compare the price of drugs offered by various suppliers and select the most favorable deals, saving money by taking advantage of best purchase pricing.

TRxADE’s programs include:

• TRxADE Exchange, which opens and widens the distribution channel to the retail, community pharmacy. A purchasing pharmacy can view products from manufacturers, buying groups, and wholesalers on a real-time and continuous basis. This approach significantly enhances the competitive spirit of the exchange where the lowest price exists for each product at any given point in time. TRxADE has become a competitive tool for all progressive entities and is recognized for its easy searching of hard-to-find generic pharmaceuticals at substantially reduced prices.  
• RX Guru™ is an industry-leading price prediction model that integrates product shortage insight into pharmacy acquisition benchmarks (“PAC”) to ascertain trends and pricing variances that result in significant purchasing opportunities. RX Guru affords members the opportunity to continuously benefit from real price purchasing opportunities that are concealed from the rest of the industry. 
• Product Shortage Database – TRxADE maintains the most comprehensive retail, specialty and acute care pharmaceutical product shortage database in the country. Other industry competitors mainly restrict their efforts to specialty and acute care product shortages and narrowly research oral generic products. TRxADE’s advanced prediction tools help members source those hard-to-find products at affordable costs in a timely and easy-to-search process. 

Management Team 

Trxade’s management team is rich in expertise within the pharmaceutical supply chain and is supported by a base of advisors and contractors who are experts in related fields of the pharmaceutical sector.

Suren Ajjarapu – Chairman of the Board, Chief Executive Officer and Secretary
Suren Ajjarapu has served as Trxade’s chairman of the board, CEO and secretary since 2014, and as the chairman of the board, chief executive officer and secretary of Trxade Nevada since its inception. Ajjarapu also serves as a chairman of the board for Feeder Creek Group Inc., since March 2018. Ajjarapu formerly was a founder, CEO and chairman of Sansur Renewable Energy Inc., a company involved in developing wind power sites in the Midwest, United States; a founder, president and director of Aemetis Inc., a biofuels company (AMTX.OB); a founder, chairman and CEO of International Biofuels, a subsidiary of Aemetis Inc.; and a co-founder, COO, and director at Global Information Technology Inc., an IT outsourcing and systems design company. Ajjarapu holds an M.S. in environmental engineering from South Dakota State University, Brookings, South Dakota, and an MBA from the University of South Florida, specializing in international finance and management. Ajjarapu is also a graduate of the Venture Capital and Private Equity program at Harvard University.

Prashant Patel – Director, President and Chief Operating Officer
Prashant Patel has served as Trxade’s full-time president and COO, and as a director since the company’s acquisition of Trxade Nevada in 2014, and as the COO and president and as a director of Trxade Nevada since its inception. He has been a president and member of the board of Trxade since August 2010. Patel is a registered pharmacist and pharmaceutical consultant with over 10 years of experience in retail pharmacy and pharmaceutical logistics. He is the founder of several pharmacies in the Tampa Bay area, in Florida. Since 2008, Patel has been managing member of the APAA LLC pharmacy. Since 2007, Patel has been a vice president of Holiday Pharmacy Inc. Patel graduated from Nottingham University School of Pharmacy and practiced in the United Kingdom before obtaining his masters in Transport, Trade and Finance from Cass Business School, City University, UK.

Trxade Group Inc. (MEDS), closed Tuesday's trading session at $5.58, up 10.9344%, on 2,954 volume with 47 trades. The average volume for the last 3 months is 63,183 and the stock's 52-week low/high is $2.0999999/$10.5600004.

Recent News

• Trxade Group, Inc. (NASDAQ: MEDS) CEO Rings Nasdaq Opening Bell
• Trxade Group Inc. (NASDAQ: MEDS) to Celebrate Nasdaq Uplisting with Opening Bell on Friday
• Trxade Group to Ring Nasdaq Opening Bell on Friday, February 28, 2020